Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Future Oncology (London, England)|December 23, 2010
Circulating tumor cells in uveal melanomaVirginia Torres, Pierre Triozzi, Charis Eng, et al.
Annals of Surgical Oncology|December 21, 2019
Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility StudyKonstantinos I Votanopoulos, Steven Forsythe, Hemamylammal Sivakumar, et al.
BJU International|September 16, 2010
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trialJorge A Garcia, Tarek Mekhail, Paul Elson, et al.
Oncotarget|December 29, 2011
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effectsTaolin Yi, Paul Elson, Masato Mitsuhashi, et al.
Journal of Clinical Immunology|April 14, 2011
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostainingAnita Schwandt, Jorge A Garcia, Paul Elson, et al.
Seminars in Oncology|February 1, 2012
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesYogen Saunthararajah, Pierre Triozzi, Brian Rini, et al.
Lung Cancer (Amsterdam, Netherlands)|April 9, 2025
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance statusSafoa Addo, Thomas Lycan, David R Soto-Pantoja, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 18, 2026
Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical TrialRyan T Hughes, Sydney Smith, Thomas W Lycan, et al.
Future Oncology (London, England)|May 18, 2023
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancerRyan T Hughes, Rediet R Gebeyehu, John Mason Kalada, et al.
Melanoma Research|November 28, 2017
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanomaJason Chesney, Sanjay Awasthi, Brendan Curti, et al.
Pageof 3